Status:
COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
End-stage Kidney Disease
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Background Arteriovenous (AV) fistula is the most common vascular access for long-term hemodialysis in the end-stage renal disease (ESRD) patients. About 25% of these patients are diabetes mellitus. H...
Detailed Description
Background In Taiwan, diabetic nephropathy is the second most common cause of end-stage renal disease (ESRD), but diabetic patients engender 12% more expense for care of dialysis than non-diabetic pat...
Eligibility Criteria
Inclusion
- Patients with diabetes mellitus (postprandial blood sugar \>140 mg/dl)
- Patients with end-stage kidney disease and is proposed to undertake chronic hemodialysis
- Patients of age 18-65 years
- The fistula is constructed in the forearm (radiocephalic fistula).
Exclusion
- Preoperative blood sugar level \>250 mg/dl or most recent HbA1c \>10%
- Recent treatment with statins within 2 weeks before evaluation for clinical trial
- Advanced liver disease
- Chronic alcoholism
- Congestive heart failure
- Coronary disease which require permanent statin therapy
- Malignancy or hematologic disorder
- Pregnancy or breastfeeding
- Past history of creation of AV fistula
- Scheduled for general anesthesia
- Emergent operation
- peripheral arterial occlusion disease
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01863914
Start Date
November 1 2012
End Date
January 31 2019
Last Update
February 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cheng Kung University Hospital
Tainan, Taiwan, 704